Market Intelligence, Clinical Progress, and High-Purity Reagents for Targeted Protein Degradation (TPD), Ubiquitin Ligase Biology, and Spermatogenesis Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for DZIP3 functional studies. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Full Length & Truncated) | DZIP3 Recombinant Protein (RING / RNA-binding domains). HEK293 expressed, >95% purity, Endotoxin <1EU/µg. Sequence Verified. Native zinc coordination preserved. | View DZIP3 Products |
| Domain Construct | DZIP3 TRIM Domain (RING-Bbox-Coiled Coil). Isolated ligase domain for enzymatic assays. Theoretical MW verified. | View DZIP3 Products |
| Gene Delivery | DZIP3 Promise-ORF / Lentivirus Premade Particles. Full-length ORF for stable cell line construction. High titer (>10^8 TU/ml). | View DZIP3 Products |
| Benchmark Ab | Anti-DZIP3 (Research Grade). Recombinant positive control for western blot, IP, and ICC validation. | View DZIP3 Products |
| Functional Validator | DZIP3 siRNA Set (3 unique sequences). For knockdown verification and specificity controls. | View DZIP3 Products |
| Related Target A | STAT3. Downstream signaling target regulated by DZIP3 pathways. | View STAT3 Products |
| Related Target B | CRBN. Classic E3 ligase for TPD comparative benchmark and resistance bypass. | View CRBN Products |
| Related Target C | DAZL (DAZ-like). Autosomal homolog in spermatogenesis pathway. Functional partner for PPI assays. | View DAZL Products |
| Related Target D | TRIM28 (KAP1). Related TRIM family E3 ligase. Essential for TRIM domain comparative studies. | View TRIM28 Products |
| Related Target E | DAZ1 (Deleted in Azoospermia 1). X-linked direct interactor. Critical for RNA granule formation studies. | View DAZ1 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ternary Complex & Ligase Activity Assays | Domain-specific (RING) and full-length proteins with strict >95% purity and Theoretical MW verification for SPR/AlphaScreen. |
| Subfamily Counter Screening (E3 Ligases) | Ortholog and homolog panel proteins strictly verified by mass spectrometry and sequence alignment. |
| Lack of Robust Controls | Sequence-verified recombinant control antibodies and precise Promise-ORF delivery tools included. |
| Target Validation & False Positives | Validated siRNA sets included for rigorous specificity and knock-out/knock-down phenotype checks. |
| Zinc Finger Domain Folding & Stability | HEK293 Expression System with supplemental Zn²⁺ culture conditions. Purity >95% confirmed by SDS-PAGE. Proper tertiary structure preservation for ligase activity. |
| Low Endogenous Expression Levels | High-titer Lentivirus Particles (>10^8 TU/ml) for stable overexpression. EF1α/CMV hybrid promoter options for germline cell compatibility. |
| TRIM Family Cross-Reactivity | Strict Sequence Verification by Mass Spectrometry. DZIP3-specific antigen regions (AA 1-350) distinguished from TRIM28/TRIM24 homologs. |
| DAZ Domain Binding Specificity | Co-expression systems available. DAZL/DAZ1 partner proteins as matched controls for pull-down assays. |
Live DZIP3 R&D Tracker
Research activity in ubiquitin ligase biology and male infertility indications evolves continuously. Access the latest global research status directly:
- View Active Clinical Trials
- Latest Resistance Research & Ubiquitination Studies
- Recent Patent Filings
Global Research Landscape & Future Outlook
DZIP3 (also designated TRIM69) represents an emerging target in ubiquitin ligase biology with dual functions as an RNA-binding E3 ubiquitin ligase. The current research frontier spans two major directions: (1) Targeted Protein Degradation (TPD) – as the field looks beyond classic CRBN and VHL ligases, DZIP3 offers a novel E3 ligase handle with tissue-specific and tumor-enriched expression, enabling resistance bypass and expanded degradable proteome; (2) Spermatogenesis & RNA Metabolism – DZIP3 functions as a TRIM family member critical for spermiogenesis through interaction with DAZ family proteins, stress granule formation, and viral RNA sensing. Emerging studies also implicate DZIP3 in hepatocellular carcinoma and germ cell biology. Demand for high-quality recombinant TRIM domains and full-length proteins is accelerating for structural biology, enzymatic assays, and chemical probe development.
Competitive Modality & Research Focus Snapshot
| Modality | Research Application / Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC / TPD Degrader | Early-stage Biotech, Academic Spin-offs | Solid Tumors, Breast Cancer | Ternary Complex Validation (Need High-Purity RING-domain proteins) |
| Small Molecule Inhibitor | Preclinical Discovery CROs | Hepatocellular Carcinoma | Ligase Activity Assay (Need High-Concentration WT Proteins) |
| RNAi / ASO | Emerging RNA Biotech | Refractory Cancers | Knockdown Specificity Assay (Need Benchmark siRNA & Antibodies) |
| Chemical Probe Development | E3 Ligase Inhibitors | Male Contraception | TRIM Domain Protein (High purity, enzymatically active) |
| Functional Genomics | siRNA/shRNA Knockdown | Infertility Research | Validated siRNA with Lentivirus Expression Systems |
| Biochemical Assays | Ubiquitination Cascade | Cancer Biology | Full-length DZIP3 with Native Zinc Coordination |
| Protein Interaction | Co-IP / Pull-down | Germ Cell Biology | DAZL/DAZ1 Partner Protein Controls |